Status:
COMPLETED
RCT on Adjuvant TACE After Hepatectomy for HCC
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
We hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve ...
Detailed Description
Liver resection is the mainstay of curative treatment for hepatocellular carcinoma (HCC). However, recurrence is common after surgery and most occurs in the liver. Transarterial chemoembolisation (TAC...
Eligibility Criteria
Inclusion
- HCC patients received curative hepatectomy with negative resection margin
- Age from 18 to 70
- Child-Pugh class A
- ASA class I to III
- ECOG performance status Grade 0 or 1
Exclusion
- Patients receiving concomitant local ablation or previous TACE
- Main portal vein tumour thrombus extraction during hepatectomy
- Tumour arising from caudate lobe
- Presence of extra-hepatic disease
- Very early HCC with solitary tumour and size \< 2cm
- Impaired liver function with either clinically detected ascites, hepatic encephalopathy, serum albumin \< 25g/L or bilirubin \> 50micromol/L
- Renal impairment with creatinine \> 200micromol/L
- Severe concurrent medical illness persisting \> 6 weeks after hepatectomy
- History of other cancer
- Hepatic artery anomaly making TACE not possible
- Allergy to cisplatin or lipiodol
- Pregnant woman
- Informed consent not available
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT01512407
Start Date
November 1 2011
End Date
December 1 2019
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, China